RNXT: RenovoRx Inc Market Cap to Revenue

Symbol and logo of brand RenovoRx Corp (RNXT)

RenovoRx, Inc. (RNXT) is scaling profits through low-cost catheter production and patent protection. The current price-to-sales ratio visualizes market demand, where 18.10 shows the current value of the metric. Growth is based on the implementation of RenovoTAMP for targeted treatment of gastrointestinal tumors, while restrained expenses under the control of focused management ensure strict adherence to clinical trial timelines.

RNXT: renovorx.com Price-to-Revenue Ratio 04/03/2025 - 11/15/2026

Metric breakdowns and analytics for RenovoRx (RNXT)

- stock value and consensus price forecast:
Stock Price RenovoRx|RNXT - Analyst Consensus Forecast
- market capitalization information:
Market Valuation RenovoRx Corporation|RNXT - Enterprise Value
- book value of equity indicators:
Accounting Value of a Share RenovoRx|RNXT - Company Book Value|Market Value to Book Value renovorx.com|RNXT - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital RenovoRx, Inc.|RNXT - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio renovorx.com|RNXT - Company Debts|Debts to Book Value RenovoRx, Inc.|RNXT - Company Long-Term Liabilities|Company Short-Term Debt RenovoRx|Immediate Liquidity renovorx.com
- earnings and valuation multiples information:
RNXT - Company Net Income|Expected Net Income RenovoRx, Inc.|RNXT - Price to Earnings Ratio|Price to Future Earnings Ratio RenovoRx, Inc.|RNXT - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation RenovoRx Corporation|RNXT - Operating profit EBITDA|Net earnings per share for the last four quarters RenovoRx|RNXT - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months renovorx.com|RNXT - Earnings growth in current year|Expected earnings per share growth for next year RenovoRx, Inc.
- total revenue and sales volume data:
RNXT - Company Sales|Company Future Sales RenovoRx Inc|RNXT - Price-to-Revenue Ratio|Forward Price to Sales RenovoRx|RNXT - Sales Growth YoY (Last Twelve Months)
Fundamental company analysis:RNXT - RenovoRx Corp
Mass-produced product of renovorx.com

RenovoRx, Inc. (RNXT) is developing a specialized local delivery system for chemotherapeutic agents to treat pancreatic cancer. By analyzing the company's P/S ratio dynamics, an investor can see the relationship between the business's market value and its annual sales volume. This multiple determines how many dollars of capitalization are attributed to each unit of revenue, reflecting market expectations for product scaling. High values typically signal that the market is betting on a future technological breakthrough.

Who RenovoRx, Inc. competes with

P/S Multiple TriSalus Life Sciences, Inc. (TLSI)|P/S Multiple PMCB (PharmaCyte Biotech)